Literature DB >> 17351490

The anaesthetic and intensive care of status epilepticus.

Martin Holtkamp1.   

Abstract

PURPOSE OF REVIEW: Status epilepticus refractory to first and second-line anticonvulsants represents an outstanding challenge to the medical team. This review covers new insights into the anaesthetic and intensive care of status epilepticus. RECENT
FINDINGS: In the anaesthetic treatment of status epilepticus, barbiturates, midazolam, or propofol are the drugs of choice, but the lack of controlled prospective data as yet does not allow the recommendation of a preference for one of the substances, unequivocally. Recent observational studies reported on inhalational anaesthetics and supplementary nonanaesthetics such as levetiracetam or topiramate that may be administered if status epilepticus is not controlled by intravenous anaesthetics. Nonpharmacological approaches including resective surgery, brain stimulation, and hypothermia may be applied in selected patients, only. Psychogenic nonepileptic status epilepticus commonly mimics refractory generalized convulsive status epilepticus, and clinical features discerning the two conditions are presented. The underlying cause is the major contributor for a difficult-to-treat 'malignant' course of status epilepticus and together with age determines mortality and functional outcome.
SUMMARY: The common substances administered for the anaesthetic treatment of status epilepticus require assessment in a prospective randomized controlled trial. Alternative pharmacological or nonpharmacological approaches need further studies as well before they can be recommended as part of the therapeutic regime.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351490     DOI: 10.1097/WCO.0b013e328042bacb

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  17 in total

Review 1.  Management of refractory status epilepticus in adults: still more questions than answers.

Authors:  Andrea O Rossetti; Daniel H Lowenstein
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

Review 2.  Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.

Authors:  Annamaria Vezzani; Raymond Dingledine; Andrea O Rossetti
Journal:  Expert Rev Neurother       Date:  2015       Impact factor: 4.618

3.  A randomized trial for the treatment of refractory status epilepticus.

Authors:  Andrea O Rossetti; Tracey A Milligan; Serge Vulliémoz; Costas Michaelides; Manuel Bertschi; Jong Woo Lee
Journal:  Neurocrit Care       Date:  2011-02       Impact factor: 3.210

4.  Intravenous levetiracetam terminates refractory focal status epilepticus.

Authors:  Nicholas S Abend; Nicole Florance; Richard S Finkel; Daniel J Licht; Dennis J Dlugos
Journal:  Neurocrit Care       Date:  2009       Impact factor: 3.210

Review 5.  Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults.

Authors:  Martin Holtkamp
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

6.  Treatment of pediatric refractory status epilepticus with topiramate.

Authors:  Başak Nur Akyildiz; Sefer Kumandaş
Journal:  Childs Nerv Syst       Date:  2011-03-26       Impact factor: 1.475

Review 7.  Treatment of Refractory and Super-refractory Status Epilepticus.

Authors:  Samhitha Rai; Frank W Drislane
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

8.  Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy.

Authors:  Andrea O Rossetti; Giancarlo Logroscino; Tracey A Milligan; Costas Michaelides; Christiane Ruffieux; Edward B Bromfield
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

9.  Treatment of cerebellar masses.

Authors:  Mahmut Edip Gurol; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2008-03       Impact factor: 3.598

Review 10.  Management of intracerebral hemorrhage.

Authors:  Mahmut Edip Gurol; Steven M Greenberg
Journal:  Curr Atheroscler Rep       Date:  2008-08       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.